Poly(GP), neurofilament and grey matter deficits in expansion carriers.

TitlePoly(GP), neurofilament and grey matter deficits in expansion carriers.
Publication TypeJournal Article
Year of Publication2018
AuteursMeeter, LHH, Gendron, TF, Sias, AC, Jiskoot, LC, Russo, SP, Kaat, LDonker, Papma, JM, Panman, JL, van der Ende, EL, Dopper, EG, Franzen, S, Graff, C, Boxer, AL, Rosen, HJ, Sanchez-Valle, R, Galimberti, D, Pijnenburg, YAL, Benussi, L, Ghidoni, R, Borroni, B, Laforce, Jr, R, Del Campo, M, Teunissen, CE, van Minkelen, R, Rojas, JC, Coppola, G, Geschwind, DH, Rademakers, R, Karydas, AM, Öijerstedt, L, Scarpini, E, Binetti, G, Padovani, A, Cash, DM, Dick, KM, Bocchetta, M, Miller, BL, Rohrer, JD, Petrucelli, L, van Swieten, JC, Lee, SE
JournalAnn Clin Transl Neurol
Date Published2018 May

Objective: To evaluate poly(GP), a dipeptide repeat protein, and neurofilament light chain (NfL) as biomarkers in presymptomatic repeat expansion carriers and patients with associated frontotemporal dementia. Additionally, to investigate the relationship of poly(GP) with indicators of neurodegeneration as measured by NfL and grey matter volume.Methods: We measured poly(GP) and NfL levels in cerebrospinal fluid (CSF) from 25 presymptomatic expansion carriers, 64 symptomatic expansion carriers with dementia, and 12 noncarriers. We explored associations with grey matter volumes using region of interest and voxel-wise analyses.Results: Poly(GP) was present in expansion carriers and absent in noncarriers (specificity 100%, sensitivity 97%). Presymptomatic carriers had lower poly(GP) levels than symptomatic carriers. NfL levels were higher in symptomatic carriers than in presymptomatic carriers and healthy noncarriers. NfL was highest in patients with concomitant motor neuron disease, and correlated with disease severity and survival. Associations between poly(GP) levels and small grey matter regions emerged but did not survive multiple comparison correction, while higher NfL levels were associated with atrophy in frontotemporoparietal cortices and the thalamus.Interpretation: This study of expansion carriers reveals that: (1) poly(GP) levels discriminate presymptomatic and symptomatic expansion carriers from noncarriers, but are not associated with indicators of neurodegeneration; and (2) NfL levels are associated with grey matter atrophy, disease severity, and shorter survival. Together, poly(GP) and NfL show promise as complementary biomarkers for clinical trials for associated frontotemporal dementia, with poly(GP) as a potential marker for target engagement and NfL as a marker of disease activity and progression.

Alternate JournalAnn Clin Transl Neurol
PubMed ID29761121
PubMed Central IDPMC5945959
Grant ListMR/M008525/1 / / Medical Research Council / United Kingdom
R35 NS097261 / NS / NINDS NIH HHS / United States